Serum apolipoprotein-A1 as a possible biomarker for monitoring treatment of canine leishmaniosis

Escribano D., Tvarijonaviciute A., KOCATÜRK M., Joaquin Ceron J., Pardo-Marin L., Torrecillas A., ...More

COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, vol.49, pp.82-87, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49
  • Publication Date: 2016
  • Doi Number: 10.1016/j.cimid.2016.10.002
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.82-87
  • Keywords: Leishmaniosis, Dogs, Apolipoprotein A1, Treatment monitoring, VISCERAL LEISHMANIASIS, PROTEINS, DOGS, IDENTIFICATION, PROTEOMICS, DIAGNOSIS
  • Bursa Uludag University Affiliated: Yes


The aims of this study were: the identification of proteins differentially represented in the serum proteome of dogs with leishmaniosis after treatment and the verification of one selected protein as a possible biomarker for treatment monitoring. Serum samples from five dogs with leishmaniosis, before and after treatment were pooled into two groups and analysed using 2-dimensional electrophoresis followed by mass spectrometry analysis (MS). The MS analysis allowed the identification of 8 proteins differently expressed. APO-A1 was selected and an immunoturbidimetric assay was validated for its measurement in dogs. Significantly decreased concentrations of APO-A1 in dogs with leishmaniosis and a significant increase after a good response to the treatment were observed, suggesting that APO-A1 could be a potential biomarker of treatment monitoring with the advantages of an automated measurement. (C) 2016 Elsevier Ltd. All rights reserved.